.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Mallinckrodt
Citi
Baxter
McKinsey
Boehringer Ingelheim
Covington
Cerilliant
Cipla
UBS
Federal Trade Commission

Generated: September 20, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 6,011,049 protect, and when does it expire?


Patent ► Subscribe protects PRELAY and is included in one NDA.

This patent has forty-five patent family members in thirty-six countries.

This patent has expired prematurely due to non-payment of maintenance fees. See details below.

Summary for Patent: ► Subscribe

Title: Combinations for diabetes
Abstract:Combinations of a glitazone antidiabetic agent and a biguanide antidiabetic agent, and optionally a sulfonylurea antidiabetic agent, are useful for treating diabetes mellitus and improving glycemic control.
Inventor(s): Whitcomb; Randall Wayne (Ann Arbor, MI)
Assignee: Warner-Lambert Company (Morris Plains, NJ)
Application Number:09/189,132
Patent Claim Types:
see list of patent claims
Use; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Sankyo
PRELAY
troglitazone
TABLET;ORAL020719-001Jan 29, 1997DISCNNoNo► Subscribe► Subscribe USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS AND BIGUANIDES IN THE TREATMENT OF TYPE II DIABETES
Sankyo
PRELAY
troglitazone
TABLET;ORAL020719-003Aug 4, 1997DISCNNoNo► Subscribe► Subscribe USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS AND BIGUANIDES IN THE TREATMENT OF TYPE II DIABETES
Sankyo
PRELAY
troglitazone
TABLET;ORAL020719-002Jan 29, 1997DISCNNoNo► Subscribe► Subscribe USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS AND BIGUANIDES IN THE TREATMENT OF TYPE II DIABETES
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: ► Subscribe

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,859,037 Sulfonylurea-glitazone combinations for diabetes► Subscribe
5,972,973 Sulfonylurea-glitazone combinations for diabetes► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina011829► Subscribe
Argentina020973► Subscribe
Austria293980► Subscribe
Australia5347399► Subscribe
Australia5590898► Subscribe
Australia741215► Subscribe
Bulgaria103671► Subscribe
Brazil9714505► Subscribe
Canada2272478► Subscribe
Canada2345524► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Novartis
Teva
Chubb
Cantor Fitzgerald
Julphar
Express Scripts
Argus Health
Covington
Federal Trade Commission
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot